STRS Ohio’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$33.1M Sell
74,163
-4,115
-5% -$1.92M 0.13% 158
2025
Q4
$35.5M Sell
78,278
-2,347
-3% -$1.01M 0.13% 148
2025
Q3
$31.6M Sell
80,625
-32,133
-28% -$13.4M 0.12% 181
2025
Q2
$50.2M Buy
112,758
+34,907
+45% +$16.1M 0.19% 106
2025
Q1
$37.7M Sell
77,851
-680
-0.9% -$317K 0.16% 134
2024
Q4
$31.6M Sell
78,531
-9,807
-11% -$4.55M 0.13% 184
2024
Q3
$41.1M Sell
88,338
-1,371
-2% -$659K 0.16% 150
2024
Q2
$42M Sell
89,709
-3,229
-3% -$1.4M 0.17% 139
2024
Q1
$38.8M Sell
92,938
-5,015
-5% -$2.12M 0.15% 153
2023
Q4
$39.9M Sell
97,953
-4,161
-4% -$1.54M 0.17% 151
2023
Q3
$35.5M Sell
102,114
-3,011
-3% -$1.05M 0.16% 159
2023
Q2
$37M Sell
105,125
-4,344
-4% -$1.46M 0.16% 160
2023
Q1
$34.5M Buy
109,469
+131
+0.1% +$39.3K 0.15% 176
2022
Q4
$31.6M Sell
109,338
-6,357
-5% -$1.94M 0.14% 199
2022
Q3
$33.5M Sell
115,695
-586
-0.5% -$169K 0.16% 168
2022
Q2
$32.8M Sell
116,281
-1,357
-1% -$363K 0.15% 180
2022
Q1
$30.7M Buy
117,638
+8,207
+7% +$1.95M 0.11% 221
2021
Q4
$24M Sell
109,431
-2,688
-2% -$523K 0.08% 271
2021
Q3
$20.3M Sell
112,119
-7,461
-6% -$1.46M 0.08% 286
2021
Q2
$24.1M Sell
119,580
-559
-0.5% -$117K 0.09% 269
2021
Q1
$25.8M Sell
120,139
-10,159
-8% -$2.23M 0.1% 246
2020
Q4
$30.8M Sell
130,298
-153,194
-54% -$35.1M 0.12% 204
2020
Q3
$77.1M Sell
283,492
-30,232
-10% -$8.34M 0.32% 65
2020
Q2
$91.1M Sell
313,724
-11,685
-4% -$3.17M 0.4% 53
2020
Q1
$77.4M Sell
325,409
-7,266
-2% -$1.67M 0.41% 58
2019
Q4
$72.8M Sell
332,675
-7,246
-2% -$1.47M 0.31% 79
2019
Q3
$57.6M Sell
339,921
-2,046
-0.6% -$362K 0.25% 98
2019
Q2
$62.7M Buy
341,967
+284
+0.1% +$49.6K 0.28% 89
2019
Q1
$62.9M Buy
341,683
+578
+0.2% +$107K 0.28% 86
2018
Q4
$56.5M Buy
341,105
+1,056
+0.3% +$183K 0.29% 92
2018
Q3
$65.5M Sell
340,049
-32,193
-9% -$5.73M 0.29% 87
2018
Q2
$63.3M Sell
372,242
-9,929
-3% -$1.54M 0.27% 100
2018
Q1
$62.3M Sell
382,171
-9,650
-2% -$1.58M 0.28% 109
2017
Q4
$58.7M Buy
391,821
+13,232
+3% +$1.96M 0.25% 122
2017
Q3
$57.6M Buy
378,589
+38,724
+11% +$5.83M 0.25% 120
2017
Q2
$43.8M Buy
339,865
+5,824
+2% +$701K 0.2% 153
2017
Q1
$36.5M Sell
334,041
-3,674
-1% -$323K 0.16% 187
2016
Q4
$24.9M Sell
337,715
-25,604
-7% -$2.08M 0.11% 234
2016
Q3
$31.7M Buy
363,319
+16,980
+5% +$1.6M 0.14% 200
2016
Q2
$29.8M Buy
346,339
+31,241
+10% +$2.7M 0.13% 208
2016
Q1
$25M Buy
315,098
+15,531
+5% +$1.4M 0.11% 230
2015
Q4
$37.7M Buy
299,567
+179
+0.1% +$21.6K 0.17% 167
2015
Q3
$31.2M Buy
299,388
+1,232
+0.4% +$158K 0.15% 187
2015
Q2
$36.8M Buy
298,156
+11,087
+4% +$1.4M 0.16% 183
2015
Q1
$33.9M Buy
287,069
+280,428
+4,223% +$33.6M 0.15% 204
2014
Q4
$789K Buy
6,641
+4,285
+182% +$483K ﹤0.01% 937
2014
Q3
$265K Hold
2,356
﹤0.01% 1398
2014
Q2
$223K Hold
2,356
﹤0.01% 1436
2014
Q1
$167K Hold
2,356
﹤0.01% 1478
2013
Q4
$175K Hold
2,356
﹤0.01% 1482
2013
Q3
$179K Buy
2,356
+2,148
+1,033% +$171K ﹤0.01% 1523
2013
Q2
$17K Buy
+208
New +$15.3K ﹤0.01% 1807

Other funds holding VRTX

STRS Ohio's VRTX Position: Q1 2026 in Review

STRS Ohio reduced its Vertex Pharmaceuticals (VRTX) stake by 5.3% in Q1 2026, selling an estimated $1.92M and leaving 74,163 shares worth $33.1M. The position accounts for 0.13% of the portfolio, ranked #158.

STRS Ohio first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $91.1M in Q2 2020. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • STRS Ohio held 74,163 shares of Vertex Pharmaceuticals worth $33.1M as of Q1 2026.
  • STRS Ohio sold 4,115 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.92M.
  • Vertex Pharmaceuticals made up 0.13% of STRS Ohio's portfolio in Q1 2026, its #158 holding.
  • STRS Ohio first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • STRS Ohio's Vertex Pharmaceuticals position peaked at $91.1M in Q2 2020.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on STRS Ohio's 13F filing for Q1 2026, filed 24 Apr 2026.